Tuesday’s analyst upgrades and downgrades

RBC raised Cenovus to $47 from $45 and Vermilion to $24 from $22, while TD Cowen lifted Finning to $115 from $106 after citing record backlog of $3.8B and strong demand trends. TerraVest was mixed, with EBITDA of $75M roughly in line but the target cut to $172 from $178, while DRI Healthcare Trust beat on revenue at $50.6M and EBITDA of $52.8M, prompting a target increase to $23.50. Several other names saw target changes mostly tied to softer outlooks or valuation calls, including Interfor, Onex, Pizza Pizza Royalty, PRO REIT and Thomson Reuters.

Analysis

The clearest signal is not the target hikes themselves, but the widening gap between operational confidence and public-market positioning. CVE and DHT are the highest-quality “self-help plus balance sheet” stories here: both now have enough near-term cash generation visibility that incremental operating improvements should de-rate their risk premium faster than the sell-side has been willing to model. In CVE’s case, the market is still underpricing the optionality embedded in a larger, more integrated oil sands platform; the second-order effect is that a future capital program can shift from growth for growth’s sake toward debottlenecking and synergies, which tends to lift returns on capital more than headline volumes.

For the industrial names, the message is that backlog quality matters more than near-term prints. Finning and Bird both appear to be entering a phase where mix, not just volume, drives margin durability: mining support intensity, data-center power, and infrastructure award wins create longer-duration revenue streams that are less cyclical than the market is assuming. TerraVest is the interesting nuance — the stock has already priced in a lot of growth, so the upside is increasingly tied to data-center tank backlog visibility; absent that, the market may keep discounting the multiple even if fundamentals remain solid.

The weakest setup is in consumer-sensitive royalty and mall-adjacent exposure where macro is still overpowering micro. PZA looks like a classic yield trap after the dividend reset: the near-term issue is not earnings quality but the credibility reset required for income investors to return, which can take multiple quarters. TRI’s target cut reinforces that investors are still paying too much for perceived defensiveness in businesses where AI-driven displacement and pricing normalization can quietly compress terminal growth expectations over the next 12–24 months.

Key Decisions for Investors

• Long CVE vs. short a basket of lower-quality Canadian E&Ps for a 6-12 month horizon: CVE’s setup combines cash flow visibility, synergy optionality, and lower reinvestment intensity; expect relative outperformance if crude stays range-bound and execution remains clean.
• Initiate a long DHT.U.TO position on any post-print weakness with a 3-6 month view: the stock should rerate first on margin durability and then on transaction optionality; risk is slower-than-expected deployment cadence, but downside appears limited by cash flow yield.
• Pair long FTT.TO against short PZA.TO for a 3-6 month relative-value trade: Finning benefits from mining/infrastructure capex and backlog conversion, while PZA faces a tougher re-rating path after the dividend cut and weak consumer backdrop.
• Take profits selectively in TVK.TO rather than chase upside here: the market is already capitalizing some data-center upside; upside remains if backlog confirms, but risk/reward is less attractive unless new order visibility improves over the next 1-2 quarters.
• Use TRI weakness as a candidate short on rallies over a 6-12 month horizon: the market may still be overvaluing structural stability; any AI/productivity narrative should be tested against slower growth and multiple compression.